
|Articles|February 1, 1998
- Psychiatric Times Vol 15 No 2
- Volume 15
- Issue 2
Alzheimer's Unit
Author(s)Richard M. Berlin, MD
Every evening, just when quiet comes, she awakens on the prowl.
Advertisement
Every evening,
just when quiet comes,
she awakens on the prowl.
Men spared from longing
float like seaweed
and hear her chant,
relentless as the thousand
tongues of waves.
A few understand
her body's invitation,
the deep taste of salt.
But none recall
the night before,
reviving in her sea.
And when by chance
they kiss and click
like shells in the surf,
a door closes,
and their rhythm is an ocean
where memories swim with starlight
over the chanting swells.
Articles in this issue
almost 29 years ago
Commentary: The Moral High (Low?) Ground of Assisted Suicidealmost 29 years ago
The (Unintended) Consequences of Mental Health Parity Policyalmost 29 years ago
The Psychiatrist's Role in Choosing a Nursing Homealmost 29 years ago
Patient Choice at Center of Battle over Medicare Law; Suit Challenges Limitsalmost 29 years ago
ERISA May Shield HMO Liability: Texas Law Under Firealmost 29 years ago
U.S. Psychiatric Congress Honors Excellencealmost 29 years ago
Congressman Introduces ERISA Reformalmost 29 years ago
Is It Depression or Is It Dementia?almost 29 years ago
'Patient Dumping'-Mentally Ill Get ShortchangedAdvertisement
Related to this article

Digital memory tests flag subtle preclinical Alzheimer changes, especially with neocortical tau; scalable tools may boost future trial screening.

BCG vaccination curbs tau tangles in mice by boosting microglial cleanup, fueling hopes for human trials to reduce dementia risk.

Sabirnetug phase 2 Alzheimer trial misses cognitive endpoint despite lowering amyloid, prompting Acumen to halt development and open-label extension plans.

HHS updates its national dementia plan, prioritizing risk reduction, early detection, biomarkers, and faster diagnostics and treatments through new FDA, CMS, and ARPA-H initiatives.

Neflamapimod misses its main DLB endpoint, but biomarker and subgroup signals suggest IL-1β pathway impact and may justify a phase 3 trial.

Breakthrough Alzheimer updates: UK adaptive platform trial tests repurposed drugs, new phase 2/3 therapies advance, and sleep disruption emerges as a treatable risk factor.

Sleep disruption fuels Alzheimer risk via apnea, fragmentation, and inflammation; improving consolidated sleep, medication review, and sleep-specialist teamwork may protect cognition.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Cannabis Use Prevalent In Substance-Related Adolescent Emergency Care: Insights From Kevin Xu, MD
2
Schizo-Obsessed! Untangling the Overlap Between Obsessive Compulsive Disorder and Schizophrenia
3
Promoting Literacy to Improve Child Development: Reading Model Boosts Efforts
4
Lumateperone Shows Significant and Rapid Improvement in Bipolar Mania
5

